SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioventix Regulatory News (BVXP)

Share Price Information for Bioventix (BVXP)

Share Price is delayed by 15 minutes
Get Live Data
1,625.00    75.00 (4.84%)
Bid:
1,600.00
Ask:
1,650.00
Spread: 50.00 (3.125%)
Market Cap: £84.90m
BVXP Live PriceLast checked at - London Stock Exchange

Intraday Bioventix Share Chart

Director/PDMR Shareholding

31 Jan 2023 17:03

RNS Number : 4761O
BioVentix PLC
31 January 2023
 

Bioventix plc

("Bioventix" or the "Company")

 

Director/PDMR Shareholdings and Issue of Equity

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the following Directors have dealt in the Company's ordinary shares of 5 pence each (the "Ordinary Shares"):

 

Director

Role

Options over Ordinary Shares exercised

Ordinary Shares sold

Sale price per Ordinary Share

Ordinary Shares held on Admission

% of issued share capital held on Admission

Ian Nicholson

Non-Executive Chairman

1,600

1,600

3,750

15,500

0.3%

Peter Harrison

Chief Executive Officer

-

57,588

3,750

359,088

6.9%

Nicholas McCooke

Non-Executive Director

2,752

2,752

3,750

-

-

 

The options over Ordinary Shares ("Options") were exercised at a price of 1350 pence per Ordinary Share pursuant to the Company's 2013 EMI Share Option Scheme, details of which can be found at www.bioventix.com. In addition, a current employee exercised 2,000 Options.

 

Issue of Equity

 

The Company has applied for 6,352 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and that dealings will commence in the new Ordinary Shares on 6 February 2023. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

The total number of Ordinary Shares in issue following Admission will be 5,215,685 and the Company holds no shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 5,215,685.

 

The above figure of 5,215,685 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information please contact:

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001

finnCap Ltd

Geoff Nash/Simon Hicks

Alice Lane

 

Corporate Finance

ECM

Tel: 020 7220 0500

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1,350p

1,600

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750

1,600

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750p

57,558

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1,350p

2,752

d)

Aggregated information:

· Aggregated volume

· Price

 

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3,750p

2,752

d)

Aggregated information:

· Aggregated volume

· Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXFFDEEDEFA
Date   Source Headline
18th May 20268:45 amRNSHolding(s) in Company
28th Apr 20263:45 pmRNSDirector Dealing
20th Apr 202611:54 amRNSShare Options Awarded
13th Apr 20267:00 amRNSDirector Dealing
8th Apr 20264:20 pmRNSDirector Dealing
30th Mar 20267:00 amRNSInterim Results
24th Feb 20267:00 amRNSAppointment of Non-Executive Director
4th Dec 20253:59 pmRNSResult of AGM
26th Nov 20258:50 amRNSDirector Dealing
11th Nov 20257:00 amRNSPosting of Annual Report and Notice of AGM
4th Nov 20254:12 pmRNSDirector Dealing
30th Oct 20257:00 amRNSDirector Dealing
27th Oct 20253:53 pmRNSDirector Dealing
27th Oct 20257:00 amRNSResults for the year ended 30 June 2025
13th Aug 20252:19 pmRNSHolding(s) in Company
28th Apr 20255:13 pmRNSDirector Dealing
11th Apr 20257:00 amRNSExercise of Options and Issue of Equity
31st Mar 20257:00 amRNSInterim Results
24th Dec 20249:14 amRNSDirector Dealing
6th Dec 20247:00 amRNSResult of AGM
4th Dec 20243:34 pmRNSHolding(s) in Company
22nd Nov 20243:56 pmRNSDirector/PDMR Shareholding
8th Nov 20247:57 amRNSNotice of AGM
31st Oct 20247:00 amRNSDirector/PDMR Shareholding
28th Oct 20247:00 amRNSResults for the year ended 30 June 2024
25th Oct 202410:37 amRNSHolding(s) in Company
16th Oct 20241:51 pmRNSHolding(s) in Company
30th Apr 20247:00 amRNSDirector/PDMR Shareholding
12th Apr 202411:05 amRNSHolding(s) in Company
25th Mar 20247:00 amRNSInterim Results
29th Jan 20243:15 pmRNSDirector/PDMR Shareholding
7th Dec 20233:26 pmRNSResult of AGM
28th Nov 20233:26 pmRNSDirector/PDMR Shareholding
16th Nov 202312:40 pmRNSHolding(s) in Company
10th Nov 20234:23 pmRNSPosting of Annual Report and Notice of AGM
7th Nov 202312:07 pmRNSHolding(s) in Company
1st Nov 20234:07 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSResults for the year ended 30 June 2023
25th Sep 20234:28 pmRNSHolding(s) in Company
19th Sep 20232:29 pmRNSHolding(s) in Company
24th Jul 20237:00 amRNSHolding(s) in Company
6th Jul 20232:48 pmRNSHolding(s) in Company
30th May 20237:00 amRNSBoard Appointment
19th May 20237:00 amRNSDirector/PDMR Shareholdings and Issue of Equity
25th Apr 202310:35 amRNSDirector/PDMR Shareholding
11th Apr 20232:45 pmRNSHolding(s) in Company
31st Mar 20232:45 pmRNSDirector/PDMR Shareholding
27th Mar 20237:00 amRNSInterim Statement
8th Mar 20235:50 pmRNSHolding(s) in Company
31st Jan 20235:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.